PRVB News and Press, Provention Bio Inc. From 09/19/22

Provention Bio ( NASDAQ: PRVB ) has announced that the Co. has appointed Sarah O'Brien as Chief People Officer. "Sarah joins us at a key juncture, as we work to scale and grow Provention Bio while staying relentlessly focused on our purpose to intercept and prevent life-th...

Provention Bio Announces Senior Leadership Addition PR Newswire RED BANK, N.J. , Sept. 19, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disea...

Provention Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference PR Newswire RED BANK, N.J. , Sept. 6, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing ...

Provention Bio ( NASDAQ: PRVB ) has secured a $125M term loan facility from Hercules Capital. The term loan facility provides for up to $125M of term loans in the aggregate, available to be funded in up to five tranches. The first tranche of $25M was drawn at closing. ...

Provention Bio Announces $125 Million Term Loan Facility with Hercules Capital PR Newswire RED BANK, N.J. , Aug. 31, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preven...

BLA was delayed again to October/November due to FDA's request around PK data. Uncertainty around Teplizumab remains, and we are not a big fan of the FDA's recent request and delay in BLA. The company's warrant structure looks messy; PRVB has a long history of punishing investors ...

Whenever a small drugmaker fails to earn approval for a new product, its shares are likely to drop. But these regulatory headwinds can sometimes create excellent buying opportunities in the volatile biotech industry, provided the company in question can address regulators' concerns and even...

Provention Bio, Inc. (PRVB) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Robert Doody - Vice President, Investor Relations Thierry Chauche - Chief Financial Officer Ashleigh Palmer - Co-Founder, President, Chief Executive Office...

Provention Bio press release ( NASDAQ: PRVB ): Q2 GAAP EPS of -$0.46 beats by $0.04 . Revenue of $0.75M beats by $0.05M . The company expects its cash-based operating expenses to be in the range of $27.0M to $31.0M for the third quarter of 2022. Based on ...

Provention Bio Reports Second Quarter 2022 Financial Results and Provides Business Update PR Newswire -Teplizumab Biologics License Application (BLA) user fee goal date extended to November 17, 2022 - -Company completes $60.0 million private placement- ...